ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 60 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,540 | +289.6% | 2,000 | 0.0% | 0.00% | – |
Q2 2023 | $652 | +65100.0% | 2,000 | 0.0% | 0.00% | -100.0% |
Q1 2023 | $1 | 0.0% | 2,000 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $1 | -100.0% | 2,000 | -33.3% | 0.00% | -50.0% |
Q3 2022 | $2,000 | -33.3% | 3,000 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $3,000 | -66.7% | 3,000 | 0.0% | 0.00% | -66.7% |
Q1 2022 | $9,000 | 0.0% | 3,000 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $9,000 | -30.8% | 3,000 | 0.0% | 0.01% | -33.3% |
Q3 2021 | $13,000 | -27.8% | 3,000 | +50.0% | 0.01% | -30.8% |
Q4 2020 | $18,000 | 0.0% | 2,000 | 0.0% | 0.01% | -31.6% |
Q1 2020 | $18,000 | +200.0% | 2,000 | +100.0% | 0.02% | +280.0% |
Q4 2019 | $6,000 | -25.0% | 1,000 | 0.0% | 0.01% | -16.7% |
Q3 2019 | $8,000 | -42.9% | 1,000 | 0.0% | 0.01% | -50.0% |
Q2 2019 | $14,000 | +180.0% | 1,000 | 0.0% | 0.01% | +140.0% |
Q1 2019 | $5,000 | +66.7% | 1,000 | 0.0% | 0.01% | +66.7% |
Q4 2018 | $3,000 | -62.5% | 1,000 | 0.0% | 0.00% | -57.1% |
Q3 2018 | $8,000 | – | 1,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Beryl Capital Management LLC | 4,898,927 | $6,246,132 | 0.70% |
Yakira Capital Management, Inc. | 620,019 | $790,524 | 0.22% |
Crystalline Management Inc. | 230,817 | $294,292 | 0.21% |
DELTEC ASSET MANAGEMENT LLC | 475,000 | $605,625 | 0.14% |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,283,979 | $2,912,073 | 0.12% |
PenderFund Capital Management Ltd. | 123,444 | $213 | 0.06% |
FIFTH LANE CAPITAL, LP | 100,000 | $127,000 | 0.04% |
CSS LLC/IL | 476,831 | $607,960 | 0.04% |
Penserra Capital Management LLC | 220,858 | $280 | 0.01% |
King Wealth Management Group | 16,000 | $20 | 0.00% |